Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.43 |
| ▸ | ITGAL | P20701 | 3/20 | 0.43 |
| ▸ | MME | P08473 | 4/20 | 0.42 |
| ▸ | ACE | P12821 | 4/20 | 0.42 |
| ▸ | CPA1 | P15085 | 3/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.42 |
| ▸ | FPR2 | P25090 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16267725 | 1.00 | CTSS (0.55) | CTSSCTSKPPARGPPARAALDH1A1 | |
| SCHEMBL9849060 | 1.00 | CTSS (0.55) | CTSSCTSKPPARGPPARAALDH1A1 | |
| SCHEMBL16267699 | 0.88 | CTSS (0.52) | CTSSCTSKALDH1A1KMT2A | |
| SCHEMBL9849180 | 0.88 | CTSS (0.52) | CTSSCTSKALDH1A1KMT2A | |
| SCHEMBL9849175 | 0.88 | CTSS (0.52) | CTSSCTSKALDH1A1KMT2A | |
| SCHEMBL3560345 | 0.86 | CTSS (0.73) | CTSSCTSKPPARGPPARAACE | |
| SCHEMBL3560344 | 0.86 | CTSS (0.73) | CTSSCTSKPPARGPPARAACE | |
| SCHEMBL21243755 | 0.86 | CTSS (0.73) | CTSSCTSKPPARGPPARAACE | |
| SCHEMBL29363717 | 0.86 | CTSS (0.73) | CTSSCTSKPPARGPPARAACE | |
| SCHEMBL2153481 | 0.85 | CTSS (0.48) | CTSSCTSKPPARGPPARAITGB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742158-B2 | Protease inhibitors | TaiMed Biologies, Inc. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-20130158261-A1 | PROTEASE INHIBITORS | TAIMED BIOLOGICS, INC. (TW) | 2013-06-20 | — | — | US | disclosed |
| US-8410300-B2 | Protease inhibitors | TAIMED BIOLOGICS, INC. (TW) | 2013-04-02 | — | — | US | disclosed |
| EP-2258681-B1 | Aromatic Derivatives as HIV Aspartyl Protease Inhibitors | TAIMED BIOLOG INC (TW) | 2012-09-26 | — | — | EP | disclosed |
| EP-2258680-A2 | Aromatic derivatives as HIV aspartyl protease inhibitors | Ambrilia Biopharma Inc. (CA) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258681-A2 | Aromatic Derivatives as HIV Aspartyl Protease Inhibitors | Ambrilia Biopharma Inc. (CA) | 2010-12-08 | — | — | EP | disclosed |
| US-20100184974-A1 | Protease Inhibitors | AMBRILIA BIOPHARMA INC. (CA) | 2010-07-22 | — | — | US | disclosed |
| EP-1575914-A1 | AROMATIC DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | Procyon Biopharma Inc. (CA) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004056764-A1 | AROMATIC DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | PROCYON BIOPHARMA INC. (CA) | 2004-07-08 | — | — | WO | disclosed |
| US-6632816-B1 | Aromatic derivatives as HIV aspartyl protease inhibitors | PHARMACOR INC. (CA) | 2003-10-14 | — | — | US | disclosed |
| EP-0421436-A2 | Substituted carboxytetrahydroisoquinolines and derivatives thereof having pharmaceutical activity | WARNER-LAMBERT COMPANY (US) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184974-A1 | Protease Inhibitors | PREP, CTRL, CTRB1 | CTSS 41/4885CTSK 150/4885PPARG 4588/4885 |
| US-20130158261-A1 | PROTEASE INHIBITORS | PREP, CTRL, CTRB1 | CTSS 41/4885CTSK 150/4885PPARG 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.